DDInter1094 DDInter1676
Lorlatinib is a third-generation ALK tyrosine kinase inhibitor (TKI) for patients with ALK-positive metastatic non-small cell lung cancer which was first approved by the US FDA in November of 2018. It was subsequently approved by the EMA in 2019 for the treatment of select patients with previously treated advanced ALK-positive non-small cell lung cancer, followed by an expanded approval in 2022 to include lorlatinib as a first-line treatment option in advanced ALK-positive NSCLC.
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Lorlatinib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Lidocaine
Lorlatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Acetohexamide
Lorlatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Betrixaban
Lorlatinib {u} may lead to a major life threatening interaction when taken with {v} Venetoclax
Lorlatinib {u} may lead to a major life threatening interaction when taken with {v} Lurbinectedin
Lorlatinib may cause a minor interaction that can limit clinical effects when taken with Lidocaine
Lorlatinib may cause a moderate interaction that could exacerbate diseases when taken with Acetohexamide
Lorlatinib may cause a moderate interaction that could exacerbate diseases when taken with Betrixaban
Lorlatinib may lead to a major life threatening interaction when taken with Venetoclax
Lorlatinib may lead to a major life threatening interaction when taken with Lurbinectedin